Dosage Forms. Tablet: 500 mg, 750 mg
Common FDA Label Indication, Dosing, and Titration.
1. Osteoarthritis: 1000-2000 mg po daily or bid
2. Rheumatoid arthritis: 1000-2000 mg po daily or bid
1. Soft tissue injury: 1000-2000 mg po daily or bid
MOA. Nabumetone is a prodrug, biotransformed into 6-methoxy-2-naphthylacetic acid (6MNA), a nonselective inhibitor of cyclo-oxygenase-1 (COX-1) and cyclo-oxygenase-2 (COX-2), and reversibly alters platelet function and prolongs bleeding time.
Drug Characteristics: Nabumetone
Medication Safety Issues: Nabumetone
Drug Interactions: Nabumetone
Adverse Reactions: Nabumetone
Efficacy Monitoring Parameters. Decreased pain and improved range of motion.
Toxicity Monitoring Parameters. Severe skin rash, black tarry stools, chest pains, yellowing of eyes or skin, change in urination; monitor CBC, LFTs, SCr, fecal occult blood tests if chronic use.
Key Patient Counseling Points. Take with food or milk to decrease GI upset.
Clinical Pearls. Elderly patients are at increased risk of GI ulceration. Patients with underlying cardiac dysfunction are at increased risk of cardiovascular effects. Use lowest dose for shortest period of time to minimize toxicity.